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irritable bowel, chronic widespread 
pain, chronic fatigue and related 
syndromes are prevalent and 
highly overlapping in the general 
population: DanfunD
Marie Weinreich petersen1*, Andreas Schröder1, torben Jørgensen2,3,4, eva Ørnbøl1, 
thomas Meinertz Dantoft2, Marie eliasen2, Michael eriksen Benros  5 & per fink1
prevalence of functional somatic syndromes (fSS) in the general population varies with observed 
overlap between syndromes. However, studies including a range of fSS are sparse. We investigated 
prevalence and characteristics of various fSS and the unifying diagnostic construct bodily distress 
syndrome (BDS), and identified mutual overlap of the FSS and their overlap with BDS. We included 
a stratified subsample of 1590 adults from a randomly selected Danish general population sample 
(n = 7493). Telephonic diagnostic interviews performed by three trained physicians were used to 
identify individuals with FSS and BDS. Prevalence of overall FSS was 9.3%; 3.8% for irritable bowel, 
2.2% for chronic widespread pain, 6.1% for chronic fatigue, 1.5% for whiplash associated disorders, and 
0.9% for multiple chemical sensitivity. Prevalence of BDS was 10.7% where 2.0% had the multi-organ 
type. fSS were highly overlapping with low likelihood of having a “pure” type. Diagnostic agreement 
of FSS and BDS was 92.0%. Multi-syndromatic FSS and multi-organ BDS were associated with female 
sex, poor health, physical limitations, and comorbidity. fSS are highly prevalent and overlapping, and 
multi-syndromatic cases are most affected. BDS captured the majority of FSS and may improve clinical 
management, making the distinction between multi- and mono-syndromatic patients easier.
Functional somatic syndromes (FSS), such as irritable bowel syndrome (IBS), fibromyalgia/chronic widespread 
pain (FM/CWP), chronic fatigue syndrome (CFS), whiplash associated disorders (WAD), and multiple chemical 
sensitivity (MCS), are prevalent in various medical settings and cause great impairment in patients and high 
health care costs for society. A variety of other terms are used in the literature for these syndromes, central sen-
sitization syndromes1 and medically unexplained symptoms2 among others, which underlines the very different 
conceptualization of these health conditions in current medicine. However, regardless the clinician’s a-priori 
conceptualisation, the present lack of objective clinical signs or reproducible paraclinical findings constitutes a 
diagnostic challenge as the diagnoses in clinical practise rely on subjective symptom reports, exclusion of relevant 
differential diagnoses, and the medical history3–9.
Reviews on IBS, FM, and CFS have shown varying prevalence in general populations: 1–45% for IBS6,10–13, 
0.5–9% for FM5,14–16, and 0.1–2.8% for CFS17–20. One population-based study has found a prevalence of WAD 
of 1.4–2.9%21. For MCS, reviews of population-based prevalence also vary tremendously: One review presented 
prevalence of physician-diagnosed MCS of 0.5% reviews while another have reported a prevalence of MCS of 
between 1 and 15%22,23.
The considerable variation in prevalence may be attributed to the different diagnostic criteria used for each 
FSS. Furthermore, a substantial overlap of symptoms between various FSS diagnoses has been shown, indicating 
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that the syndromes are not entirely independent conditions but may be different representations of a common 
phenomenon or belong to a family of related disorders7,8,24–29. In order to meet this issue, the unifying diagnostic 
construct, bodily distress syndrome (BDS) has been proposed30,31. It presents with four subtypes of symptom 
clusters; a cardiopulmonary (CP) type, a gastrointestinal (GI) type, a musculoskeletal (MS) type, and a general 
symptoms (GS)/fatigue type. BDS can be divided into a single (or oligo)-organ type with symptoms from one or 
two organ systems and a multi-organ type with symptoms from three or four organ systems. By encompassing a 
range of FSS, it presents a new way of defining and delimitating these syndromes taking into account the overlaps 
between FSS30–32. The BDS diagnostic construct has recently been verified in a sample from the general Danish 
population33, but until now, only one study about the epidemiology of BDS in a general population-based sample 
(n = 9656) has been conducted34, and further studies on BDS are needed.
FSS and BDS constitute two diagnostic approaches to the umbrella classification functional somatic disorders 
(FSD) drafted by the European research network EURONET-SOMA35, and therefore this term will be used when 
addressing both FSS and BDS in this paper. As multiple definitions of the various FSS exist, and the choice of 
criteria for defining individual FSS may therefore be difficult16,20,36–38, we will use more broad symptom criteria 
without symptom overlap in order to gain a genuine picture of the overlap of FSS. Therefore, we use irritable 
bowel (IB) for describing IBS, CWP to describe FM, and chronic fatigue (CF) for describing CFS.
Many epidemiological studies within FSD use self-reported questionnaires for identification of FSD cases. 
While this method is cost-effective and appropriate for screening purposes, it only provides a likelihood of having 
the condition and cannot be used for establishing clinical diagnoses. Instead, a diagnostic interview performed 
by trained physicians may better delimitate individuals with clinically relevant disorders from individuals with 
normal bodily reactions and to rule out relevant physical and mental differential diagnoses. This is particularly 
important within the field of FSD where diagnoses are based on somatic symptom profiles39. Using self-reported 
questionnaires may therefore induce misclassification of both false-positives and false-negatives40.
The objectives of this study were to establish prevalence and characteristics of a range of FSDs using two diag-
nostic approaches: 1) Five FSS (IB, CWP, CF, WAD and MCS) and 2) BDS in the general Danish population using 
a diagnostic interview performed by trained physicians. Moreover, to study the mutual overlaps of the five FSS 
and test if the unifying BDS construct succeed in capturing the FSS diagnoses.
Results
Study participants. A stratified sample of 2450 (32.7%) participants were invited to participate in the inter-
view, and 1590 (64.9%) accepted and completed. Their median age was 54 years (IQR: 44–63 years), 59.3% were 
women, and 67.9% had more than three years of vocational training. Comparison analyses revealed no differ-
ences between the interviewees and decliners regarding sex and vocational training. However, with a median 
age of 56 years (IQR: 46–64, p = 0.003), decliners were older than interviewees and had lower risk of a poor 
self-perceived health (22.7% of interviewees had a poor self-perceived health compared to 16.7% of decliners, RR: 
1.4, 95% CI: 1.2–1.6, p < 0.001) and limitations in daily activities (26.2% of interviewees had limitations in daily 
activities compared to 19.2% of decliners, RR: 1.4, 95% CI: 1.2–1.6, p < 0.001).
For 60 participants, a diagnosis could not be established; either because the participants were under further 
examination by their family physician or hospital, or because the interviewer could not obtain sufficient informa-
tion during the interview. In these cases, we conservatively rated the participant as not having an FSD.
functional somatic syndromes. Weighted prevalence of having at least one FSS was 9.3% (95% CI: 8.1–
10.6), and all FSS were generally more prevalent in women (Table 1). FSS prevalence seemed to be consistent 
across age groups (Supplementary Material Table 1).
Prevalence of cases with only one FSS, i.e. having a “pure” type of FSS, was 5.5% (95% CI: 4.5–6.8) (Table 1). These 
cases tended to be younger than non-cases, and they had higher risk of having a poor health and physical and mental 
comorbidities. However, these associations were only statistically significant for some of the pure FSS (Table 1).
A substantial fraction of cases within each FSS type had more than one FSS, and 20 out of 26 possible combi-
nations of the five FSS were found. The likelihood of having only one FSS in its pure form was low ranging from 
18.8% for CWP to 43.5% for IB (Fig. 1).
Compared with non-cases, multi-syndromatic FSS cases were generally younger and they had higher risk of being 
unemployed, to have a poor self-perceived health, to have limitations in daily activities, to have physical and mental 
comorbidities, and to have received a FSS diagnosis by a physician (Table 1). In contrast to cases with only one FSS, the 
majority of these associations were strong and statistically significant. Hence, multi-syndromatic FSS cases seemed to 
be stronger associated with several negative outcomes than those only having one FSS. Data on age, sex, social factors, 
physical health, and comorbidity are displayed as percentages in Supplementary Material Table 2.
Bodily distress syndrome. BDS had a weighted prevalence of 10.5% (95% CI: 9.3–11.9) (Table 2). As for 
FSS, prevalence of BDS was also consistent across age groups (Supplementary Material Table 1).
Cases of BDS were younger than non-cases, and they had high risk of being unemployed, having a poor 
health, limitations in daily activities, physical and mental comorbidity, and to have received a FSS diagnosis by 
a physician (Table 2). All associations were especially strong for the multi-organ type of BDS. Data on age, sex, 
social factors, physical health, and comorbidity are displayed as percentages in Supplementary Material Table 3.
overlaps of functional somatic syndromes and bodily distress syndrome. The prevalence of those 
having at least one FSS and/or BDS was 12.1% (95% CI: 10.7–13.6). Overall diagnostic agreement between any 
of the five FSS and BDS was 92.0% (95% CI: 90.6–93.3) (Table 3), corresponding to a kappa of 0.78, p < 0.0001. 
Compared to FSS, BDS had a sensitivity of 90.2% (95% CI: 86.6–93.1) and a specificity of 92.6% (95% CI: 90.9–
94.0). A Receiver Operating Characteristics curve is displayed in Supplementary Material Fig. 1.
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Prevalence 
of having 
no FSS 
N = 1222, 
90.7% 
(95% CI 
89.4–91.9)
Prevalence of having one of the below FSS in pure 
form N = 202, 5.5% (95% CI: 4.5–6.8)
Prevalence of having FSS irrespective of FSS 
comorbidity N = 357, 9.3% (95% CI 8.1–10.6)
IB pure
CWP 
pure CF pure
WAD 
pure
MCS 
pure IB CWP CF WAD MCS One FSS Two FSS
≥Three 
FSS
N = 70 
1.5% 
(1.1–2.0)
N = 18 
0.5% 
(0.3–0.8)
N = 92 
2.7% 
(2.1–3.6)
N = 10 
0.4% 
(0.2–0.9)
N = 12 
0.4% 
(0.2–0.9)
N = 161 
3.8% 
(3.1–4.6)
N = 96 
2.2% 
(1.8–2.8)
N = 228 
6.1% 
(5.1–7.2)
N = 53 
1.5% 
(1.0–2.0)
N = 33 
0.9% 
(0.6–1.3)
N = 202 
5.5% 
(4.5–6.8)
N = 110 
2.7% 
(2.1–3.5)
N = 45 
1.1% 
(0.8–1.5)
Basic
Age, Median 
(IQR)
54.0 
(44.0–63.0)
46 
(32–60)
55.5 
(43–66)
51 (43.5–
58.5)
44 
(33–53)
53.5 
(51–58)
48 
(36–58)
52 (45.5–
59)
49 (41–
57.5)
50 
(42–58)
54 
(49–59)
50 
(41–59)
49 
(41–58)
50 
(42–57)
Sex; Women vs 
men, RR* 1 (Ref.)
1.2 
(1.0–1.4)
1.2 
(0.9–1.7)
1.3 
(1.1–1.5)
1.0 
(0.6–1.7)
1.7 
(1.4–2.0)
1.4 
(1.2–1.5)
1.4 
(1.2–1.6)
1.4 
(1.2–1.5)
1.3 
(1.0–1.5)
1.4 
(1.1–1.7)
1.3 
(1.1–1.4)
1.4 
(1.3–1.6)
1.4 
(1.2–1.7)
Social**
Cohabiting, RR 1 (Ref.) 0.9 (0.7–1.0)
1.1 
(0.9–1.4)
1.0 
(0.9–1.1)
1.0 
(0.7–1.5)
0.9 
(0.6–1.3)
0.9 
(0.8–1.0)
1.0 
(0.8–1.1)
0.9 
(0.9–1.0)
0.9 
(0.8–1.1)
0.9 
(0.7–1.1)
1.0 
(0.9–1.1)
0.9 
(0.8–1.1)
0.9 
(0.7–1.1)
Formerly 
employed, RR 1 (Ref.)
1.0 
(0.7–1.4)
1.5 
(0.7–3.0)
1.1 
(0.8–1.5)
1.1 
(0.3–3.3)
1.2 
(0.6–2.6)
1.4 
(1.2–1.9)
2.0 
(1.5–2.5)
1.4 
(1.2–1.8)
1.6 
(1.1–2.3)
1.3 
(0.8–2.2)
1.1 
(0.9–1.3)
1.6 
(1.2–2.1)
3.0 
(2.1–4.1)
Never been 
employed, RR 1 (Ref.)
0.4 
(0.06–
2.9)
5.3 (0.9–
32.2) — — —
0.9 
(0.3–2.5)
3.6 (1.2–
11.0)
1.2 
(0.5–3.0)
2.1 (0.3–
14.2)
4.5 (0.6–
31.3)
0.5 
(0.1–2.0)
1.9 
(0.8–4.6)
2.4 (0.4–
15.8)
Vocational 
training, OR 1 (Ref.)
1.4 
(0.8–2.2)
1.0 
(0.4–2.5)
1.1 
(0.7–1.7)
0.4 
(0.1–1.2)
1.1 
(0.4–3.1)
1.1 
(0.8–1.5)
1.1 
(0.7–1.6)
1.0 
(0.8–1.3)
1.1 
(0.7–1.8)
1.0 
(0.5–2.0)
1.1 
(0.8–1.5)
1.0 
(0.7–1.4)
1.1 
(0.6–1.9)
Physical health**
Poor self-
perceived 
healtha, RR
1 (Ref.) 1.4 (0.9–2.3)
2.1 
(1.1–4.1)
2.9 
(2.3–3.8)
2.2 
(0.9–5.7)
2.3 
(1.2–4.5)
2.4 
(1.9–3.0)
3.4 
(2.8–4.2)
3.2 
(2.7–3.8)
3.3 
(2.5–4.3)
2.5 
(1.7–3.8)
2.3 
(1.8–2.9)
3.0 
(2.3–3.7)
3.9 
(3.1–5.0)
Being limited in 
daily activitiesb, 
RR
1 (Ref.) 1.3 (0.9–2.0)
1.7 
(0.9–3.3)
2.3 
(1.8–3.0)
1.7 
(0.7–4.5)
1.9 
(1.0–3.8)
2.1 
(1.7–2.6)
3.2 
(2.6–3.8)
2.8 
(2.4–3.3)
3.1 
(2.4–4.0)
2.4 
(1.7–3.4)
1.9 
(1.5–2.3)
2.8 
(2.3–3.4)
3.5 
(2.8–4.3)
GP diagnosis and comorbidity**
Having FSS 
according to a 
physicianc, RR
1 (Ref.) 2.9 (2.5–3.5)
2.0 
(1.2–3.4)
1.3 
(1.1–1.5) —
0.7 
(0.2–2.4)
3.0 
(2.6–3.5)
2.7 
(2.3–3.2)
2.3 
(2.0–2.7)
1.6 
(1.4–1.8)
2.2 
(1.6–2.9)
2.1 
(1.7–2.5)
2.6 
(2.2–3.2)
3.1 
(2.6–3.7)
Physical 
comorbidity, RR 1 (Ref.)
1.5 
(1.3–1.8)
1.3 
(1.0–1.6)
1.1 
(1.0–1.3) — —
1.4 
(1.3–1.5)
1.3 
(1.2–1.5)
1.3 
(1.2–1.4)
1.6 
(1.4–1.8)
1.5 
(1.2–1.8)
1.4 
(1.3–1.5)
1.3 
(1.2–1.5)
1.4 
(1.2–1.6)
Mental 
comorbidity, RR 1 (Ref.)
1.3 
(0.6–2.7)
1.7 
(0.4–6.3)
2.9 
(1.9–4.6) —
1.2 
(0.1–8.2)
2.4 
(1.6–3.6)
3.2 
(2.1–4.9)
3.3 
(2.4–4.6)
1.0 
(0.4–2.7)
1.8 
(0.7–4.5)
1.9 
(1.3–2.9)
3.0 
(2.0–4.6)
3.4 
(1.9–5.9)
Table 1. Prevalence and characteristics of participants with functional somatic syndromes. Abbreviations: 
FSS = functional somatic syndrome; IB = irritable bowel; CWP = chronic widespread pain; CF = chronic 
fatigue; WAD = whiplash associated disorders; MCS = multiple chemical sensitivity. IQR = interquartile range; 
RR = relative risk; OR = odds ratio. *Adjusted for age. **Adjusted for age and sex. aFair or poor health89. bAll 
of/most of/some of the time89. cReceived a diagnosis of at least one of the following: Irritable bowel syndrome, 
fibromyalgia, chronic fatigue syndrome, whiplash associated disorders, multiple chemical sensitivity by a 
general practitioner. Bold: Significantly different from participants not having any FSS (P < 0.05). “-“could not 
be estimated because of too few observations.
Figure 1. Overlap of functional somatic syndromes.
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Discussion
To our knowledge, this is the first study to simultaneously investigate prevalence and characteristics of the three 
most investigated FSS (IB, CWP, CF) and two exposure-defined FSS (MCS, WAD) in the general population by 
means of a clinical diagnostic research interview performed by trained family physicians over the telephone. 
Moreover, we also assessed a new unifying diagnostic construct, BDS, and its ability to capture the more estab-
lished diagnoses. Overall weighted prevalence of having at least one FSS was 9.3%, and while most of the overall 
case group had only one FSS, the majority within each FSS type had FSS comorbidity. Overall weighted prev-
alence of BDS was 10.5% (95% CI: 9.3–11.9), and this constituted mostly single-organ BDS, i.e. patients with 
symptoms from one or two organ systems. Compared to non-cases, multi-syndromic FSS and multi-organ BDS 
were strongly associated with unemployment, poor health, limitations in daily activities, and physical and mental 
comorbidity. These associations were less strong for those only having one FSS or single-organ BDS indicating 
that individuals with multiple FSD are more burdened. Overall diagnostic agreement between FSS and BDS was 
high (92.0%, kappa 0.78), sensitivity and specificity of BDS were high (>90%), and the BDS construct captured 
the majority of FSS categories.
Other population-based studies including several FSS simultaneously have reported prevalence of IBS ranging 
from 3.5% to 12.6%, prevalence of FM ranging from 1.9% to 9.4%, and prevalence of CFS/CF ranging from 0.8% 
to 12.6%34,41–44. Hence, our results on prevalence of IB, CWP, and CF are in line with these studies, even though 
No BDS Single-organ BDS CP subtype GI subtype MS subtype GS subtype Multi-organ BDS
N = 1177 89.5% 
(88.1–90.7)
N = 327 8.5% 
(7.3–9.7)
N = 47 1.3% 
(0.9–1.9)
N = 173 4.0% 
(3.3–4.8)
N = 107 3.0% 
(2.3–3.8)
N = 111 3.1% 
(2.4–4.0)
N = 86 2.0% 
(1.6–2.6)
Basic
Age, Median (IQR) 55.0 (45.0–64.0) 52.0 (42.0–60.0) 51.0 (37.0–59.0) 53.0 (42.0–61.1) 53.0 (47.0–60.0) 49.0 (40.0–56.0) 48.5 (39.0–57.0)
Sex; Women vs men, RR* 1 (Ref.) 1.3 (1.2–1.4) 1.2 (1.0–1.5) 1.3 (1.1–1.4) 1.4 (1.2–1.5) 1.3 (1.2–1.5) 1.5 (1.3–1.7)
Social**
Cohabiting, RR 1 (Ref.) 0.9 (0.8–1.0) 0.9 (0.7–1.1) 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.9 (0.7–1.0) 0.9 (0.7–1.0)
Formerly employed, RR 1 (Ref.) 1.3 (1.1–1.6) 1.4 (0.9–2.2) 1.3 (1.0–1.6) 1.7 (1.3–2.3) 1.5 (1.2–2.1) 1.6 (1.2–2.2)
Never been employed, RR 1 (Ref.) 0.8 (0.3–2.0) 0.7 (0.1–4.8) 0.4 (0.1–1.8) 2.6 (0.8–8.1) 0.6 (0.2–3.0) 2.5 (1.1–6.1)
Vocational training, OR 1 (Ref.) 1.0 (0.8–1.3) 1.2 (0.7–2.1) 1.1 (0.8–1.5) 0.9 (0.6–1.3) 1.0 (0.7–1.5) 1.0 (0.7–1.6)
Physical health**
Poor self-perceived healtha, RR 1 (Ref.) 2.3 (1.9–2.8) 2.2 (1.5–3.4) 2.0 (1.5–2.6) 2.7 (2.1–3.5) 3.0 (2.4–3.8) 3.8 (3.0–4.8)
Being limited in daily activitiesb, RR 1 (Ref.) 2.1 (1.8–2.5) 2.1 (1.5–3.1) 1.6 (1.3–2.1) 2.6 (2.1–3.3) 2.7 (2.1–3.3) 2.9 (2.3–3.5)
GP diagnosis and comorbidity**
Having FSS according to a 
physicianc, RR 1 (Ref.) 2.3 (1.9–2.6) 2.0 (1.4–2.9) 2.7 (2.3–3.2) 2.2 (1.8–2.7) 1.9 (1.5–2.5) 2.6 (2.1–3.2)
Physical comorbidity, RR 1 (Ref.) 1.3 (1.3–1.5) 1.4 (1.2–1.7) 1.4 (1.3–1.5) 1.2 (1.1–1.4) 1.3 (1.2–1.5) 1.3 (1.1–1.5)
Mental comorbidity, RR 1 (Ref.) 2.8 (2.0–4.0) 3.1 (1.7–5.8) 2.7 (1.8–4.1) 2.5 (1.5–4.2) 3.9 (2.6–5.9) 4.3 (2.7–6.6)
Table 2. Prevalence and characteristics of participants with and without bodily distress syndrome. 
Abbreviations: BDS = bodily distress syndrome; CP = cardiopulmonary; GI = gastrointestinal; 
MS = musculoskeletal; GS = general symptoms type. IQR = interquartile range; RR = relative risk; OR = odds 
ratio. *Adjusted for age. **Adjusted for age and sex. aFair or poor health89. bAll of/most of/some of the time89. 
cReceived a diagnosis of at least one of the following: Irritable bowel syndrome, fibromyalgia, chronic fatigue 
syndrome, whiplash associated disorders, and multiple chemical sensitivity by a general practitioner. Bold: 
Significantly different from participants not having BDS (P < 0.05).
Diagnostic (observed) agreement; % (95% CI)
At least one FSS IB CWP CF WAD MCS
(n = 357) (n = 161) (n = 96) (n = 228) (n = 53) (n = 33)
BDS (n = 413) 92.0 (90.6–93.3) 83.5 (81.6–85.3) 79.9 (77.9–81.9) 86.1 (84.3–87.8) 76.1 (74.0–78.2) 75.2 (73.0–77.3)
Multi-organ BDS (n = 86) 82.7 (80.8–84.6) 91.2 (89.7–92.6) 94.0 (92.7–95.1) 90.1 (88.5–92.5) 93.4 (92.0–94.6) 94.3 (93.0–95.4)
Single-organ BDS (n = 327) 86.7 (84.9–88.3) 82.1(80.1–84.0) 79.9 (77.9–81.9) 81.7 (79.7–83.6) 79.4 (77.3–81.4) 78.9 (76.8–80.9)
CP subtype (n = 47) 78.0 (75.8–80.0) 88.3 (86.6–89.8) 91.1 (89.5–92.4) 85.1 (83.2–86.8) 93.9 (92.7–95.1) 95.5 (94.3–96.4)
GI subtype (n = 173) 86.7 (84.9–88.4) 94.6 (93.3–95.7) 86.2 (84.3–87.9) 83.9 (81.9–85.7) 87.2 (85.4–88.9) 88.0 (86.3–89.6)
MS subtype (n = 107) 84.1 (82.1–85.9) 87.0 (85.2–88.7) 96.3 (95.2–97.2) 88.1 (86.4–89.7) 91.8 (90.3–93.1) 92.1 (90.6–93.4)
GS subtype (n = 111) 87.6 (85.8–89.2) 87.2 (85.4–88.9) 91.1 (89.6–92.5) 95.4 (94.2–96.4) 92.4 (90.9–96.7) 91.6 (90.1–93.0)
Table 3. Diagnostic agreement between functional somatic syndromes and bodily distress syndrome. 
Abbreviations: FSS = functional somatic syndrome; IB = irritable bowel; CWP = chronic widespread pain; 
CF = chronic fatigue; WAD = whiplash associated disorders; MCS = multiple chemical sensitivity; BDS = bodily 
distress syndrome; CP = cardiopulmonary; GI = gastrointestinal; MS = musculoskeletal; GS = general 
symptoms type; CI = confidence interval.
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we found lower prevalence of IB and CWP. One reason for this could be that all mentioned studies have used 
questionnaires as method for case identification which could cause some false positive cases overestimating the 
various FSS prevalence.
To our knowledge, interviews have been used in population-based studies to study somatic symptoms45,46 
and in more selected patient samples to study prevalence of FSS and BDS30,46–48, but until now, no other 
population-based studies on interview-based FSS or BDS prevalence exist.
In a recent DanFunD study, we reported a questionnaire-based prevalence of having at least one FSS and/or 
BDS that was almost 50% higher than in the current study34. This difference may be explained by the fact that in 
the current study, we did not include participants with conventionally-defined disease that could account for the 
physical symptoms as FSD cases.
Our results on case characteristics are in line with several other studies on specific FSS
It is a consistent finding that the female sex dominates in both IBS10–13,49, FM5,14,16,50, CFS17,19,51, WAD52, and 
MCS22,23. However, one study did not find any pronounced predominance of the female sex in FM53. In that study, 
FM prevalence and sex ratio were estimated using the 2016 Fibromyalgia criteria in one sample of patients diag-
nosed with FM but no other rheumatoid or inflammatory diseases and one sample of patients diagnosed with 
rheumatoid arthritis but no FM. Since the current study includes individuals sampled from the general popula-
tion, it may to a lesser extent have such risk of selection bias.
Unemployment and the inability to maintain a job have also previously shown to be associated with both IBS10,11, 
FM16,50, and CFS17,51.
In the current study, all FSS are highly associated with self-rated poor quality of life, i.e. having a poor health 
or limitations in daily activities, which is similar to findings in other studies on IBS6,10–13,49, FM16,50, CFS17,51, 
WAD52,54,55, and MCS23.
Other studies also found high comorbidity with other diseases in all FSS. This counts for both physi-
cal5,6,14,18,22,50,52,54,56,57 and mental disease5,10,14,17–19,21–23,50–52,54,58,59 as well as other FSS6,17,21,29,51,54,56,58,59.
Studies on general populations including a range of FSS have shown the same associations34,41–45,60, and as in 
the current study, mental comorbidity seemed pronounced in CFS34,43.
Only few studies have been made on BDS, and these constitute mainly studies on clinical samples. These stud-
ies also find cases of BDS being associated with the female sex34,61,62, unemployment62–64, poor health, limitations 
in daily functioning62–65, high comorbidity with physical disease and other FSS, and mental disorders34,62,64,65.
The debate on how to understand, define, and delimitate FSD has been going on for decades7,8,24,26,27,66. It has 
divided debaters into splitters, defining the disorders as distinct entities, and lumpers arguing that all FSD are 
manifestations of the same underlying disorder26,67,68.
We found a low likelihood of having the “pure” type of each of the investigated disorders thus questioning 
the current clinical practice that focuses on one disorder at a time. Even more importantly, our results question 
the usability of specific guidelines for single (i.e. “pure”) syndromes as most patients presenting at the clinic have 
FSS comorbidities. Currently, even though it has been widely recognized in research that the FSD are not discrete 
diseases, patients are often managed based on this perspective when attending the health care system.
Our results indicate that the vast majority of e.g. patients with IBS/IB in gastroenterological departments also 
have at least one other FSS, for which they are most likely not being treated in a specialized setting69.
Current clinical practice bears the risk of neglecting those multi-syndromatic patients. Especially the shift of main 
symptoms or syndromes over time is quite often overlooked, as each FSS is assessed and treated as a distinct condition. 
In the current study, the group of multi-syndromatic individuals constituted 20 out of 26 possible combinations of the 
five investigated FSS, comprising 43.4% of all individuals with FSS in the general population. Giving each combination 
of disorders a specific assessment and treatment plan in the clinic would not be feasible. Hence, the importance of giv-
ing each patient an assessment, acknowledging all presenting symptoms, should be emphasized9,70–72.
The BDS diagnostic construct may provide a solution for this defining the FSD as a common phenomenon but 
with distinct subtypes30. The diagnostic agreement between FSS and BDS was high which has also been shown 
in studies on more selected patient samples30,32. Our results underline previous studies showing that the BDS 
concept can easily distinguish between multi-syndromic patients and those with symptoms from only one or 
two organ systems. This distinction may improve clinical management, and BDS shows a promising compromise 
between the splitters’ and lumpers’ perspectives in managing patients with FSD and in future research26,67. This 
suggested unifying phenotype construct based on empirical data may suggest a common underlying etiology 
of the FSD. Most studies into the genetic and environmental risk factors for different FSS have shown that the 
co-occurrence of FSS may be caused by shared genetics and both common (e.g. a trauma) but also specific (e.g. 
infections) environmental risk factors28,29,73,74. However, another study suggests that CWP may mainly be genet-
ically associated with fatigue59.
Whether or not these discrepancies could be attributable to methodological differences between studies is 
unclear. A main problem with studies on the various FSS is that most have focused on only one or a few syn-
dromes at a time, viewing the FSS as distinct syndromes without taking FSS comorbidity into account. In future 
research, approaching the FSD with criteria acknowledging them as being both mono- and multi-syndromatic 
conditions may lay down the avenue for better studies on their etiology.
This study has several strengths. First, the large sample of participants completing the interviews is a sub-
stantial strength in the study adding power to the statistical analyses. Second, the use of trained physicians and 
semi-structured diagnostic research interviews provides a better possibility for distinguishing between functional 
and differential diagnoses than questionnaires, self-reported diagnoses, or layman implemented interviews. The 
experienced clinicians have the capacity to judge clinical relevance and complexity of each symptom and assess 
if the symptom clusters could be a manifestation of a FSD. Hence, the case assignment was based on specialized, 
medical knowledge. Third, we assessed the FSD according to two diagnostic approaches: Five different FSS with 
distinct criteria without mutual overlap of symptoms and the unifying concept of BDS.
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However, the study also has some limitations. First, the diagnostic interviews were conducted by telephone. 
Thus, we merely relied on information from the participants and did not have access to medical records or the 
possibility of conducting further medical tests or physical clinical examinations, which is required to make an 
exhaustive, clinically valid diagnosis. Second, different traditions within each medical speciality together with 
the absence of a gold standard for diagnosing FSD might cause some cases to be falsely labelled as non-cases 
due to multi-morbidity, i.e. where conventionally defined physical disease was present together with the FSD. 
Furthermore, we cannot be completely certain of the RIFD’s ability to diagnose at a detailed level, e.g. to detect 
single subtypes of FSS and BDS. Third, using others of the multiple prevailing criteria for defining the various FSS 
may have provided us with different results, but we preferred to include criteria commonly used in epidemiologi-
cal research. Furthermore, the included criteria did not have symptom overlap which is a problem of many of the 
specialty specific definitions developed in highly selected patient samples. Moreover, the included less restrictive 
criteria may better capture the broader spectrum of FSS that may be expected in a general population sample. 
Finally, only 64.9% accepted the interview invitation, and the majority (98.3%) of those who declined was high 
scores in the symptom questionnaires. Loss of participants to the second study phase is a general limitation of the 
two-phase design75, and it might have influenced the found associations concerning characteristics of the cases 
and non-cases. However, as the results from this study are in line with results in other studies on the complete 
DanFunD cohort34,76, we believe our results to be reliable.
conclusions and perspectives
Regardless of diagnostic criteria, FSD are highly prevalent and overlapping. The impact on functioning and qual-
ity of life is considerable with strong associations with poor health, limitations in daily activities, and physi-
cal and mental comorbidity. Some pure FSS categories seem more burdensome, but cases with multiple FSS or 
multi-organ BDS are most affected. While the distinct FSS diagnoses may have some merits in specific clinical 
settings, the unifying BDS construct makes it easy to distinguish between multi-syndromic patients, who are cur-
rently in risk of being neglected, and those with symptoms from only one or two organ systems. This distinction 
may improve current clinical management of FSD.
Methods
Study participants and data collection. This study was designed as a cross-sectional two-phase study 
(Fig. 2) using data from the Danish Study of Functional Disorders (DanFunD) part two cohort77. In brief, the 
cohort was established from 2012 to 2015 with the purpose of investigating FSD in the general Danish population. 
DanFunD part two consists of 7493 (29.5%) adults sampled from the general Danish population and randomly 
obtained from the nationwide Danish Civil Registration System. In phase one, participants filled in symptom 
questionnaires for physical symptoms specific for FSS and BDS, social factors, and overall health, among others. 
Prevalence of FSS and BDS obtained from these questionnaires has been reported elsewhere34. In phase two, 
the questionnaires formed the basis for identifying a stratified subsample invited to participate in the Research 
Interview for Functional somatic Disorders (RIFD)78, derived from a modified version of the comprehensive psy-
chiatric interview Schedules of Clinical Assessment in Neuropsychiatry (SCAN)79. The RIFD interview assesses 
symptoms for a range of FSD; IBS/IB, FM/CWP, CFS/CF, WAD, MCS, and BDS, and it has shown to be a feasible 
instrument for use in large epidemiological studies for identifying individuals with FSD. In a small preliminary 
study, RIFD showed acceptable criterion validity and interrater reliability78.
The subsample was combined by a random sample of one tenth of all DanFunD part two cohort participants 
and participants with high scores on the BDS checklist80 or Whiteley-7 scale81 in the symptom questionnaires. 
For being a high score on the BDS checklist, participants had to be bothered “quite a bit” or “a lot” from symptoms 
from at least one symptom cluster and report additional impairment on ≥6 on a continuous 0–10 scale. For being 
a high score on the Whiteley-7 scale, participants had to be bothered “quite a bit” or “a lot” from symptoms and 
report additional impairment on ≥6 on a continuous 0–10 scale. All interviews were conducted by telephone by 
three trained family physicians. Detailed information on the general procedure of RIFD has been described in 
detail elsewhere78.
Written informed consent was obtained from each participant before participation.
The study was approved by the independent ethics committees the Ethical Committee of Copenhagen County 
(Ethics Committee: KA-2006-0011; H-3-2011-081; H-3-2012-0015) and the Danish Data Protection Agency.
All methods were carried out in accordance with the relevant guidelines and regulations.
Measurements. Diagnostic criteria. Post-hoc diagnostic criteria were used to assign case status on the basis 
of the obtained symptoms from the interviews (Table 4). The diagnostic criteria by Kay et al.82 for IBS/IB, the 
diagnostic criteria by White et al.83 (modified from the American College of Rheumatology 1990 FM criteria84) 
for FM/CWP, the diagnostic criteria by Chalder et al.85 for CFS-like symptoms/CF, and the diagnostic criteria 
by Fink et al.61 for BDS. Diagnostic criteria for WAD were defined as having impairing neck pain that could be 
attributed to an accident86. Diagnostic criteria for MCS were defined as having impairing symptoms believed to 
be attributed to exposure to fragrances or chemical substances87,88.
Characteristics. Cases and non-cases were described and compared by self-reported measures from the ques-
tionnaires: Cohabitation, employment, vocational training, self-perceived health, limitation in daily activities, 
and whether the participant had received a diagnosis of one of the five FSS by a physician. Self-perceived health 
and limitations in daily activities were measured with two single questions from the 12-item Short Form Health 
Survey (SF-12)89. Self-perceived health was measured on a five-point Likert scale from “excellent” to “poor”, 
and answers were dichotomized into “poor self-perceived health” (fair/poor) and “good self-perceived health” 
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(excellent/very good/good). Limitations in daily activities were measured on a five-point Likert scale (“all the 
time” to “none of the time”) dichotomized into “limited in daily activities” (all of the time/most of the time/some 
of the time) and “not limited in daily activities” (a little of the time/none of the time). The interviewer assessed 
physical comorbidity based on whether or not the participant had received diagnoses of any of the following 
pre-defined diseases: Diabetes, asthma, joint disease, cardiac disease, hypertension, and pulmonary disease. 
Furthermore, it was possible for the interviewer to register if the participant had another disease which was not 
included in the pre-defined list of diseases. Mental comorbidity was also assessed in the interview using post-hoc 
ICD-10 criteria to define any state of major depressive disorder and single items assessing anxiety disorders 
(panic attacks, social phobia, and generalized anxiety)78.
Data analysis. Data were analysed using Stata 15.0 for Windows (StataCorp LLC, College Station, USA).
Prevalence of FSS and BDS was calculated with 95% confidence intervals using weighted logistic regression 
with the interviewed sample fraction as sample weights to correct for the skewness introduced by the stratified 
sampling procedure. With information on the interview sampling mechanism (randomly selected, selected as 
high score, randomly selected but also with high score) together with information on age and sex, assignment of 
sample weights of each of the participants was made. This approach gave information on how many participants 
from the screening questionnaire sample that were represented by each of the interviewed participants, general-
izing the prevalence to the whole DanFunD part two sample of 7493 individuals75.
Difference in age between cases and non-cases were compared with a Wilcoxon-Mann-Whitney test for 
non-normally distributed data. Sex, cohabitation, employment, self-perceived health, self-perceived limitations 
in daily activities, information on obtained FSS diagnoses, and comorbidity were presented as dichotomous 
outcomes with risk ratios calculated with general linear models with binomial family and log link. Vocational 
Figure 2. Flow of study participants.
Syndrome Diagnostic criteria
Irritable bowel82 Participants with 1) abdominal pain and 2) distension and, in addition, either 3) borborygmi or 4) altering stool consistency, or both.
Chronic widespread 
pain83
Participants with 1) pain in muscles, bones, or joints; and 2) pain in shoulders, arm, or hands; and 3) pain in legs or feet; 
and 4) pain in neck, chest, or back.
Chronic fatigue85
Participants with ≥4 of the following: 1) Tiredness; 2) the need to rest more; 3) sleepiness or drowsiness; 4) problems 
starting things; 5) lack of energy; 6) less muscle strength; 7) weakness; 8) difficulties concentrating; 9) making slips of the 
tongue when speaking; 10) difficulties saying the right words; and 11) memory problems.
Whiplash associated 
disorders86 Participants stating to be bothered by impairing neck pain following an accident.
Multiple chemical 
sensitivity87,88
Participants stating to have been exposed by at least two unrelated exposures and to have been bothered by symptoms 
from at least two organ systems; at least one being the central nervous system. The symptoms should have significant 
impact on life style together with social or occupational limitation.
Bodily distress 
syndrome61
Participants with ≥3 symptoms from different symptom clusters together with impairment; 1) a cardiopulmonary 
cluster, 2) a gastrointestinal cluster, 3) a musculoskeletal cluster, 4) a general symptom cluster.
Participants having 1 or 2 symptom clusters or at least 4 symptoms across all symptom clusters single-organ bodily 
distress syndrome. Participants having ≥3 symptom clusters had multi-organ bodily distress syndrome.
Table 4. Post-hoc diagnostic criteria of functional somatic syndromes and bodily distress syndrome.
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training was presented as an ordered categorical outcome with odds ratios calculated with ordered logistic regres-
sion. Sex was adjusted for age, while social parameters, physical health, and comorbid disease were adjusted for 
age and sex.
Interviewed participants and participants declining to participate in the RIFD were compared on age, sex, 
vocational training, self-perceived health, and limitations in daily activities.
Mutual overlaps of the various FSS were estimated and shown in Venn-diagrams using the web-tool Venn 
diagram maker from the website Bioinformatics & Evolutionary Genomics90.
Diagnostic agreement between FSS and BDS was evaluated with Cohen’s Kappa, and sensitivity and specificity 
of BDS were calculated.
Data availability
The datasets generated during and/or analysed during the current study are available on reasonable request from 
the DanFunD project leader Thomas Dantoft by email: Thomas.Meinertz.Dantoft@regionh.dk.
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